Literature DB >> 23845791

Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.

Alexander R Levine1, Matthew J Meyer, Edward A Bittner, Sheri Berg, Rebecca Kalman, Anne B Stanislaus, Cheryl Ryan, Stephanie A Ball, Matthias Eikermann.   

Abstract

PURPOSE: Persistent low-level hypotension represents a barrier to discharging patients from the intensive care unit (ICU). Midodrine may be an effective adjunct to wean intravenous (IV) vasopressors and permit ICU discharge. We tested the hypothesis that midodrine, given to patients on IV vasopressors who otherwise met ICU discharge criteria, increased the magnitude of change in IV vasopressor rate.
MATERIALS AND METHODS: This was a prospective, observational study in 20 adult surgical ICU patients who met ICU discharge criteria except for an IV vasopressor requirement. We compared the change in phenylephrine equivalent rates during the day before midodrine to the change in phenylephrine equivalent rates after midodrine initiation and analyzed changes in total body fluid balance, heart rate, mean arterial pressure, and white blood cell count during this period.
RESULTS: Patients received 41.0±33.4 μg/min of phenylephrine equivalents and the change in IV vasopressor rate (slope) decreased significantly from -0.62 μg/min per hour of phenylephrine equivalents before midodrine to -2.20 μg/min per hour following the initiation of midodrine treatment (P=.012). Change in total body fluid balance, heart rate, mean arterial pressure, and white blood cell count did not correlate with change in IV vasopressor rate.
CONCLUSION: Midodrine treatment was associated with an increase in the magnitude of decline of the IV vasopressor rate. Oral midodrine may facilitate liberation of surgical ICU patients from an IV vasopressor infusion, and this may affect discharge readiness of patients from the ICU.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hypotension; ICU discharge; Intensive care unit; Intravenous vasopressors; Midodrine

Mesh:

Substances:

Year:  2013        PMID: 23845791     DOI: 10.1016/j.jcrc.2013.05.021

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  12 in total

1.  High-dose midodrine is not effective for treatment of persistent hypotension in the intensive care unit.

Authors:  Peter Santer; Matthias Eikermann
Journal:  Intensive Care Med       Date:  2021-01-08       Impact factor: 17.440

2.  Postextubation High-Flow Nasal Cannula Oxygen, Randomized Trial of an ICU Quality Improvement Intervention, and Midodrine during Recovery from Septic Shock.

Authors:  James M Walter; Jacqueline M Kruser; Paul A Reyfman; Peter H S Sporn
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

3.  Midodrine administration during critical illness: fixed-dose or titrate to response?

Authors:  Richard R Riker; David J Gagnon
Journal:  Intensive Care Med       Date:  2020-11-25       Impact factor: 17.440

4.  Late Vasopressor Administration in Patients in the ICU: A Retrospective Cohort Study.

Authors:  Elizabeth M Viglianti; Sean M Bagshaw; Rinaldo Bellomo; Joanne McPeake; Daniel J Molling; Xiao Qing Wang; Sarah Seelye; Theodore J Iwashyna
Journal:  Chest       Date:  2020-04-09       Impact factor: 9.410

5.  Letter to the Editor: "Midodrine to liberate ICU patients from intravenous vasopressors: Another negative fixed-dose trial".

Authors:  Richard R Riker; David J Gagnon
Journal:  J Crit Care       Date:  2022-02-10       Impact factor: 4.298

6.  Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial.

Authors:  Amos Lal; Vrinda Trivedi; Mahrukh S Rizvi; Amy Amsbaugh; Melissa K Myers; Khaled Saleh; Rahul Kashyap; Ognjen Gajic
Journal:  Crit Care Explor       Date:  2021-05-06

7.  Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).

Authors:  Matthew H Anstey; Bradley Wibrow; Tharusan Thevathasan; Brigit Roberts; Khushi Chhangani; Pauline Yeung Ng; Alexander Levine; Alan DiBiasio; Todd Sarge; Matthias Eikermann
Journal:  BMC Anesthesiol       Date:  2017-03-21       Impact factor: 2.217

8.  Fluid Stewardship During Critical Illness: A Call to Action.

Authors:  W Anthony Hawkins; Susan E Smith; Andrea Sikora Newsome; John R Carr; Christopher M Bland; Trisha N Branan
Journal:  J Pharm Pract       Date:  2019-06-30

9.  Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.

Authors:  Peter Santer; Matthew H Anstey; Maria D Patrocínio; Bradley Wibrow; Bijan Teja; Denys Shay; Shahzad Shaefi; Charles S Parsons; Timothy T Houle; Matthias Eikermann
Journal:  Intensive Care Med       Date:  2020-09-03       Impact factor: 17.440

10.  Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study.

Authors:  Jan-Alexis Tremblay; Philippe Laramée; Yoan Lamarche; André Denault; William Beaubien-Souligny; Anne-Julie Frenette; Loay Kontar; Karim Serri; Emmanuel Charbonney
Journal:  Ann Intensive Care       Date:  2020-09-14       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.